Berberine protects against metformin-associated lactic acidosis in induced diabetes mellitus

Authors

1 Department of Medicine Liaquat University of Medical and Health Sciences Jamshoro, Sindh, Pakistan

2 Faculty of Medicine and Allied Medical Sciences Isra University, Hyderabad, Sindh, Pakistan

3 Department of Pathology Liaquat University of Medical and Health Sciences Jamshoro, Sindh, Pakistan

Abstract

Objective(s): Causality of occurrence of metformin-associated lactic acidosis (MALA) is a clinical problem. Currently, there is no drug available to prevent MALA. The present study was conducted to evaluate the protective effect of Berberine (BBR) against MALA in induced diabetic rat model.
Materials and Methods: A sample of 75 healthy male Wistar rats was randomly selected according to inclusion and exclusion criteria. 75 male Wistar rats were randomly divided into a control and 4 experimental groups. Streptozotocin (STZ) in citrate buffer (pH 4.5) at a dose of 45 mg/kg was injected for induction of diabetes mellitus and rats achieving fasting blood glucose >250 mg/dl were included. Blood samples were collected 18 hr after the last dose of metformin and berberine. Ethical approval was taken before the study was conducted. Staistix 10.0 (USA) software was used for data analysis.
Results: Berberine decreased MALA. Metformin, metformin + BBR 50 mg/kg bwt, and metformin + BBR 100 mg/kg bwt showed serum lactate as 1.87±0.4 mmol/lL, 1.62 ± 0.44 mmol/l and 1.47± 0.45 mmol/l, respectively (P=0.0001).  Insulin resistance and liver enzymes were improved in BBR treated rats.
Conclusion: The present study reports berberine protects against MALA in streptozocin-induced diabetes mellitus.

Keywords


1.Zafar J, Nadeem D, Khan SA, Jawad Abbasi MM, Aziz F, Saeed S. Prevalence of diabetes and its correlates in urban population of Pakistan: A Cross-sectional survey. J Pak Med Assoc 2016; 66:922-927.

2.Lepelley M, Giai J, Yahiaoui N, Chanoine S, Villierr C. Lactic acidosis in diabetic population: is metformin implicated? results of a matched case-control study performed on the Type 2 diabetes population of grenoble hospital university. J Diabet Res 2016; 2106: 3545914.

3.Inzucchi SE, Bergenstal RM, Buse JB. Management of hyperglycemia in type 2 diabetes: a patient centered approach position statement of the American Diabetes Association (ADA) and European Association for the Study of Diabetes (EASD). Diabetol 2012; 55:1577–1596.

4.Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin or insulin in patients with type 2 diabetes mellitus. Progressive requirement for multiple therapies (UKPDS 49). J Am Med Assoc 2012; 281: 2005–2012.

5.Lalau JD. Lactic acidosis induced by metformin: incidence, management and prevention. Drug Safety 2010; 33:727–740.

6.Bodmer M, Meier C, Krahenbuhl S, Jick SS, Meier CR. Metformin, sulfonylureas, or other anti-diabetes drugs and the risk of lactic acidosis or hypoglycemia: a nested case-control analysis. Diabet Care 2008; 31:2086–2091.

7.Lalau JD, Race JM. Lactic acidosis in metformin treated patients. Prognostic value of arterial lactate levels and plasma metformin concentrations. Drug Safety 1999; 20:377–384.

8.Vecchio S, Protti A. Metformin-induced lactic acidosis: no one left behind. Critical Care 2011; 15:1- 107.

9.Chen L, Guo W, Zhang S, Lu W, Liao S, Li Y.  Berberine prevents high glucose-induced cell viability inhibition and apoptosis in podocytes.  Int J Clin Exp Med 2016; 9:5942-5950.

10.Ni YX. Therapeutic effect of berberine on 60 patients with type II diabetes mellitus and experimental research. Zhong Xi Yi Jie He Za Zhi 1988; 8:711–713.

11.Patel MI, Makhija SU. Effects of linezolid and metformin combination on vital biochemical functions with special reference to lactic acidosis in streptozotocin induced diabetic rats. Res J Pharm Biol Chem Sci 2013; 4:1278 -1288.

12.Li XY, Zhao ZX, Huang M, Feng R, He CY, Ma C, et al. Effect of berberine on promoting the excretion of cholesterol in high-fat diet-induced hyperlipidemic hamsters. J Transl Med 2015; 13:278.

13. Manning PJ, Sutherland WH, Walker RJ. Effect of high-dose vitamin E on insulin resistance and associated parameters in overweight subjects. Diabet Care 2004; 27:2166– 2171.

14.Tripathi H. Long-term preservation of donor corneas in glycerol for keratoplasty: exploring new protocols. Br J Ophthalmol 2016; 100:284-90.

15.Salpeter S, Greyber E, Pasternak G. Risk of fatal and non fatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev 2010; 4:CD0002967.

16.Cryer DR, Nicholas SP, Henry DH, Mills DJ, Stadel BV. Comparative outcomes study of metformin intervention versus conventional approach: the COSMIC Approach study. Diabet Care 2005; 28:539–543.

17. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group Lancet 1998; 352:854–865.

18.Yin J, Gao Z, Liu D, Liu Z, Ye J. Berberine improves glucose metabolism through induction of glycolysis. Am J Physiol Endocrinol Metab 2008; 294:E148–E156.

19.Xie P, Zhou H, Gao Y. The clinical efficacy of berberine in treatment of type 2 diabetes mellitus [article in Chinese]. Chin J Clin Healthcare 2005; 8:402–403.

20. Wei J, Wu J, Jiang J, Wang S, Wang Z. Clinical study on improvement of type 2 diabetes mellitus complicated with fatty liver treatment by berberine. Zhong Xi Yi Jie He Ganbing Za Zhi 2004; 14:334–336.

21.Lalau JD, Race JM. Lactic acidosis in metformin treated patients. Prognostic value of arterial lactate levels and plasma metformin concentrations. Drug Safety 1999; 20:377–384.

22.Guariguata L, Whiting DR, Hambleton I, Beagley J, Linnenkamp U, Shaw JE. Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabet Res Clin Prac 2013; 103:137–149.

23.Scale T, Harvey JN. Diabetes, metformin and lactic acidosis. Clin Endocrinol 2011; 74:191-196.

24.Biradar V, Moran JL, Peake SL, Peter JV. Metformin associated lactic acidosis (MALA): clinical profile and outcomes in patients admitted to the  intensive care unit. Crit Care Resusc 2010; 12:191–195.

25.Salpeter S, Greyber E, Pasternak G, Salpeter E. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev 2010; 4:CD002967.

26.Bodmer M, Meier C, Krahenbuhl S, Jick SS, Meier CR. Metformin, sulfonylureas, or other antidiabetic drugs and the risk of lactic acidosis or hypoglycemia: a nested case-control analysis. Diabet Care 2008; 31:2086–2091.

27. Wheaton WW, Weinberg SE, Hamanaka RB, Soberanes S, Sullivan LB, Anso E, et al. Metformin inhibits mitochondrial complex I of cancer cells to reduce tumorigenesis. ELife 2014; 3:e02242.

28.Erejuwa OO, Amrah S, Sulaiman SA, Wahab MS, Salam SK, Salleh MS, et al. Antioxidant protective effect of glibenclamide and metformin in combination with honey in pancreas of streptozotocin- induced diabetic rats. Int J Biol Sci 2011; 7:244-252.

29.Chowdhury TA, Wright R, Yaqoob MM. Using metformin in the presence of renal disease. Br Med J 2015; 350:h1758.

30.Calabrese AT, Coley KC, Da Pos SV, Swanson D, Rao RH. Evaluation of prescribing practices: risk of lactic acidosis with metformin therapy. Arch Intern Med 2002; 162:434–437.

31.Eurich DT, Mc Alister FA, Blackburn DR. Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review. Br Med J 2007; 335:497–501.

32.Papanas N, Maltezos E, Mikhailidis DP. Metformin and heart failure: never say never again. Expert Opin Pharmacother 2012; 13:1–8.

33.Vasisht KP, Chen SC, Peng Y, Bakris GL. Limitations of metformin use in patients with kidney disease: are they warranted? Diabet Obes Metabol 2010; 12:1079–1083.

34.Cayley Jr WE. Does metformin increase the risk of fatal or nonfatal lactic acidosis? Am Family Phys  2010; 82:1068–1070.